Trial Profile
Aprepitant in the Prevention of Delayed Emesis Induced by Moderately Emetogenic Chemotherapy (Cyclophosphamide Plus Anthracyclines) in Breast Cancer Patients: a Double-Blind Randomized Study.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Jan 2014
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Dexamethasone; Dexamethasone; Palonosetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 09 Dec 2013 Results published in the Journal of Clinical Oncology.
- 31 May 2013 Primary endpoint 'Complete-control-of-nausea-and-vomiting' has not been met.
- 31 May 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.